BioAge Labs has partnered with Novartis to tackle age-related diseases. The collaboration aims to identify and validate novel therapeutic drug targets for age-related diseases by leveraging BioAge's human longevity data and Novartis's expertise in exercise biology.
The partnership between BioAge and Novartis is expected to enhance the understanding of the biological mechanisms of aging and the beneficial effects of physical exercise, potentially leading to innovative treatment options.
Under the agreement, BioAge will receive upfront payments and research funding, with the potential for additional long-term research, development, and commercial milestones. Both companies retain the right to pursue novel targets identified during the collaboration, with reciprocal success milestones and tiered royalties available to both parties.
BioAge's proprietary discovery platform, built on exclusive access to longitudinal human aging cohorts, allows the company to apply advanced analytics and machine learning techniques to identify determinants of healthy lifespan. The collaboration with Novartis is expected to significantly expand BioAge's capacity to discover and develop novel therapeutic targets based on insights derived from this rich dataset.
The partnership between BioAge and Novartis reflects a growing recognition within the biopharmaceutical industry of the importance of understanding the biology of aging to address various diseases. The insights gained from this research could lead to novel therapeutic options and position both companies at the forefront of a field focused on longevity and healthspan enhancement.
The collaboration also highlights the importance of strategic partnerships in the biopharmaceutical sector, where shared expertise and resources can accelerate the development of innovative therapies.